Therefore, we propose the potential clinical benefit of an appropriate combination of conventional chemotherapeutic drugs with a new generation of signal-transduction inhibitors that target the HER-2/PI3K–AKT pathway for the treatment of endometrial cancer. The gene discussed is ERBB2; the disease is endometrial cancer.